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Abstract
Background: To examine trends in mortality, costs and in-hospital management and outcomes of severe COPD
exacerbations admitted in France.
Methods: Patients hospitalized from 2007 to 2012 with COPD exacerbation as the primary diagnosis were
identified from the exhaustive French medico-administrative hospitalizations database records. Four groups of
severe COPD exacerbations were defined: hospitalisation in a general ward (GW) without acute respiratory failure
(ARF), GW with ARF, ICU without invasive mechanical ventilation (MV), and ICU with MV.
Results: A 15.48 % increase in admissions from 113 276 in 2007 to 133 497 in 2012 was recorded. Age (+9.
9 months), gender (−2.5 % of male) and length of stay (−0.29 day) slightly changed while the number of ICU
admissions increased markedly (+41.78 %). In-hospital mortality rates increased (+8.06 %, p < .001) and followed
seasonal variations peaking in winter. Total hospitalizations costs increased from 602 to 678 millions euros (+12.
6 %). Pneumonia-related mortality increased (+37.2 %). A progressive replacement of chest X-ray by CT scan was
observed (−41.3 % vs +31.7 %) while fewer spirometries (−13.7 %) and bronchoscopies (−22.6 %) were performed.
Conclusion: The incidence of severe COPD exacerbations and the proportion of ICU-managed patients are still
increasing in France. Rising total costs and mortality rates especially related to pneumonia advocate for rethinking
COPD management plans.
Trial registration: Not applicable.
Keywords: COPD exacerbation, COPD management, Hospitalizations, Admissions, Deaths
Key messages
- What is the key question?
What are the precise trends in COPD admissions
triggers and management and outcomes ?
- What is the bottom line?
The incidence of severe COPD exacerbations and the
proportion of ICU-managed patients are increasing in
parallel with total costs and mortality rates especially
related to pneumonia.
- Why read on?
An exhaustive and consecutive national database ana-
lysis identified social determinants, cause of admissions
and medical acts performed and identified great changes
in the management which should be reappraised.
Background
Chronic Obstructive Pulmonary Disease (COPD) is a
frequent and devastating disease worldwide and will re-
main one of the major chronic diseases in the future [1].
Despite smoking bans in public places in most Western
countries, COPD is still ascending and, by 2030, will
remain one of the leading causes of death in Europe and
westernized countries [2, 3]. Nowadays, as the general
world population is aging, COPD patients have many
comorbid conditions interacting with the respiratory dis-
ease and contributing to the difficulty of the long-term
* Correspondence: a-bourdin@chu-montpellier.fr
1PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214,
Montpellier hospital, Montpellier, France
2Apard, Montpellier, France
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Molinari et al. Respiratory Research  (2016) 17:149 
DOI 10.1186/s12931-016-0469-6
management [4, 5]. Noteworthy, COPD-related admis-
sions are decreasing in Spain and in the US [6, 7].
Managing COPD is still challenging [8] despite critical
achievements in the field of epidemiology, definition,
mechanisms, and better understanding of the natural
history of the disease. Positive effects of prevention and
long-term management on survival and slowering of
lung function are now likely achievable [9]. COPD
affects the daily quality of life of most patients and
represents a major burden for societies through both
direct and indirect costs.
COPD exacerbations are major events in the natural
history of the disease [10]. The “frequent exacerbator”
phenotype is associated with a faster decline of lung
function and health status, and poorer prognosis regard-
ing the risks of hospitalization and death [11]. In
addition, COPD exacerbation is a dreadful experience
for patients, their relatives and the health care system
[10, 12, 13]. Strategies aimed at improving the treatment
and prevention of exacerbations remain far from being
fully effective despite growing numbers of randomized
controlled studies [14]. Current treatments do not target
etiology-specific underlying mechanisms. Besides, some
may be deleterious in the long term through increases in
the risks of local (pneumonia) or systemic adverse events
[15]. Costs related to COPD are mainly due to admis-
sions for exacerbations [16]. All these considerations
point to COPD exacerbations as a major challenge for
the medical community and encourage research to
better understand their burden, causes, outcomes and
treatments. New opportunities to exhaustively address
such questions arose in recent years since the quality
control of registries dramatically improved in France
with a policy based on three medical check-points (first,
the doctor who codes, second, the dedicated doctor who
checks and last, the payer who controls and who can
impose fines in case of discordance).
In the present study, we report the results of a study
investigating an exhaustive database of six consecutive
years of severe exacerbations of COPD leading to hospi-
talizations in France. The data were obtained from the
French admissions registry, which allows an exhaustive
assessment of various trends. We aimed to understand
whether features of COPD hospitalizations are changing
in France with regard to incidence, severity, manage-
ment, outcomes and costs.
Methods
Study design and population
This observational study used exhaustive standardized
data from the national PMSI database (“Programme
Médicalisé des Systèmes d’Information”), prospectively
collected from 2007 to 2012. This dataset contains
medico-economic information about admissions based on
the International Classification of Diseases (ICD-10) clas-
sification from both public and private hospitals in France.
It includes all data collected by healthcare providers be-
fore submission to the social welfare office. The study fo-
cuses on admissions for COPD from 2007 to 2012 (end of
stay before January 1, 2013).
Hospitalization was defined by a stay of at least one
night in a hospital. All patients with a permanent address
in France were included. Patients with codes for chronic
airway disorders other than COPD (e.g., asthma or bron-
chiectasis) were excluded in order to improve specificity.
Only stays with COPD as a primary diagnosis were con-
sidered in order to avoid stays where COPD was quoted
as a comorbidity. Sorting rules have already been
described [17] and are recalled in the Additional file 1:
Table SA1. When acute respiratory failure was used as a
primary diagnosis, the case was considered only if COPD
was confirmed as the related cause (i.e. quoted as associ-
ated diagnosis) of the acute respiratory failure.
Hospitalizations were categorized into four mutually
exclusive categories; category 1: general ward without
Acute Respiratory Failure (GW-no ARF); category 2:
general ward with Acute Respiratory Failure, (GW-ARF);
category 3: Intensive Care Unit without Mechanical
Ventilation (ICU-No MV); and category 4: Intensive
Care Unit with Mechanical Ventilation (ICU-MV). The
data collected included age, gender, length of stay, vital
status at discharge, month of discharge, patient home
address and hospitalization costs for the French Health
Care System. The top-five diagnoses quoted as related to
the exacerbation were also analyzed. The most frequently
reported medical acts relevant for managing COPD exac-
erbations were analyzed. Costs related to each stay was
computed according to French’policy which takes inflation
into account.
Socio-professional categories, CMU (Free Universal
Health Care, corresponding to the lowest socio-
economic categories, coverage rate, average household
income) in each French ‘départment’ were obtained
from the INSEE (Institut National de la Statistique et
des Études Économiques).
Statistical analysis
Hospitalization rates were standardized according to age
and gender for each French ‘départment’. Descriptive data
of quantitative variables were summarized as mean ±
standard deviation and median with interquartile range.
Unadjusted chi-square test was used for nominal or di-
chotomous variables, continuous variables were compared
with the use of the unpaired t-test or the Mann–Whitney
U test (according to the normality of the distribution,
assessed with the Shapiro-Wilk test). The Mann-Kendall
test was used to assess if there is a monotonic trend of the
variable of interest over time. A linear regression was used
Molinari et al. Respiratory Research  (2016) 17:149 Page 2 of 11
to assess the association between hospitalization rates and
economic variables. Due to large disparities of age-
distribution between regions, age-standardized maps were
built and these data were subsequently implemented in all
statistical models where regions were used. Because the
effectives are so large, virtually all of the p values are
significant which makes them less useful. Subse-
quently, strong confidence in p > 0.05 was considered
for non statistical significance. The statistical analysis
was performed by the medical statistical department
of the Montpellier University Hospital using SAS
(version 9.3; SAS Institute; Cary, NC, USA) and R
(version 3.1.1) statistical softwares.
Results
Between 2007 and 2012, 733 585 hospital admissions
corresponding to 600 662 COPD patients were recorded
in France.
Admission and demographic characteristics during the
6 years of interest and for each category of hospitalization
are presented in Table 1 (given the large numbers, p-values
are all significant and then not shown). Hospitalization
categories 1, 2, 3 and 4 concerned respectively 64.9, 20.8,
4.6 and 9.7 % of admissions. Trends are displayed in Figs. 1
and 2. The number of hospitalizations increased by 18 %
in 6 years (+24, −11, +23 and +48 % in catergories 1, 2, 3
and 4, respectively) while the overall French population
increased by 2.59 % (63.601 in 2007 vs. 65.252 million
people in 2012). Noteworthy, the proportion of patients
corresponding to category 2 (GW ARF) decreased over
time (−4.64 %, p < .001).
Mean age at admission significantly increased from
74.15 ± 12.05 year to 74.97 ± 12.17 (+9.9 months).
While men remained more numerous, the gender
ratio trend showed a move toward equilibrium
(−2.5 % of men, p < .001). Lengths of stays (9 ± 9 days)
significantly decreased by 0.29 day.
Most characteristics were significantly different depend-
ing on the categories of hospitalization. Patients admitted
in ICU requiring mechanical ventilation (category 4) were
younger (p < .001), with longer length of stay (p < .001).
In-hospital mortality increased by 8.06 % (p < .001) de-
pending on the categories of hospitalization (p < .001), the
lowest mortality rates being recorded in category 1 (GW
no ARF) and the highest in category 4 (ICU-MV). Over
the 6 years, the mortality rate significantly decreased in
ICU (category 4: from 23.6 to 20.4 %, p < .001) but in-
creased for patients admitted in the ward (category 2 and
1: +18.4 and +19.9 % respectively, p < .001).
Overall, the costs per admission decreased in all four
categories (Fig. 1) but the total costs of hospitalizations
increased from 602 044 800 euros in 2007 to 667 885
491 euros in 2012 (+10.9 % vs. 2007, p < .001). The mean
cost per admission was 3 667 ± 1 976 euros in 2012
depending on the hospitalization categories (from 9 243
for category 4 patients to 3 632 euros for category 1).
The top cost for a single stay reached 337 000 euros.
ICU contribution to overall costs remained nearly stable,
with a transfer of 4 % from the category GW-ARF to
ICU-MV (Additional file 1: Table SA3). The quoted
acute conditions associated with exacerbations are
described in Additional file 1: Table SA4. Basically, five
final related diagnoses gathered 80 to 90 % of all stays.
Upper airway infections overtook cardiac failure, pneumo-
nias, pulmonary embolism and pneumothorax) (Fig. 3). A
trend analysis identified a monotone rise in cardiac failure
(p = .024) and upper airway infection (p = .009). The trend
analysis identified a significant increase in the mortality
related to pneumonia only (Mann Kendall p-value for
trend p = .024).
Chest X-ray was the most frequent procedure per-
formed during each stay (Additional file 1: Table SA5),
followed by electrocardiogram and arterial blood gas
analysis. There was a clear decrease in chest X-ray use
(from 1.35 CXR to 0.81/stay, −40.1 %), while that of
thoracic CT scan increased (+34.4 %). These trends were
homogeneously recorded throughout the different cat-
egories of severity (Fig. 4). A monotone decrease in
bronchoscopy was noticed (−22.6 %).
Seasonality of admissions and deaths are presented in
Fig. 5a and b respectively. Data distributions were simi-
lar from 2007 to 2012. A non-uniform distribution of
annual admissions (p < .001) and deaths (p < .001) were
observed with a peak in incidence during the fall-winter
season. This non-uniform distribution was also observed
for admissions in each category. The seasonal peak was
recorded at different dates each year, close to but not
perfectly matching with FLU-peaks.
Spatial distribution of age-standardized hospitalization
rates in 2012 is presented in Fig. 6a. Nearly three-fold re-
gional heterogeneities were observed as admission rates
ranged from 236 per year for 100 000 inhabitants to 686
per year for 100 000 inhabitants (p < .001). A north to
south gradient was visually noticed. Regional variations
from 2007 to 2012 are presented in Fig. 6b, displaying
areas where COPD admissions increased the most.
Regressions between age-standardized hospitalization
rates and economic data of the inhabitants of the ‘départ-
ment’ were computerized. Lower age-standardized
hospitalization rates in 2012 were associated with
higher proportions of upper socio-professional categor-
ies (p = .004). There was no significant association with
the CMU (Free Universal Health Care) coverage rate
(p-value = 0.74). In contrast, when analyzing the vari-
ation of age-standardized hospitalization rates between
2007 and 2012 (areas were it increased the most), a
negative correlation with average household income
was found (p < .001, Adjusted R-squared = 0.304).
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Discussion
In this study, our ability to get exhaustive national con-
secutive data allowed to confidently identify three robust
trends. First, incidence increases much faster than the
population grows, especially regarding ICU-admitted
patients. Patients are older, stays are shorter and women
are more represented. Second, intra-hospital mortality
also increases despite apparent improvement in the
utilization of health care resources and the availability of
funds specifically dedicated to this disease (as shown by
Table 1 Six-year Trends in hospitalizations for COPD exacerbation in France










2007 115 600 10 239 (8.86) 5 155 (4.46) 25 227 (21.82) 74 979 (64.86)
2008 119 105 10 811 (9.08) 5 274 (4.43) 24 382 (20.47) 78 638 (66.02)
2009 124 669 12 061 (9.67) 5 912 (4.47) 24 008 (19.26) 82 688 (66.33)
2010 125 331 12 876 (10.27) 6 184 (4.93) 23 916 (19.08) 82 355 (65.71)
2011 128 847 13 611 (10.56) 6 130 (4.76) 24 192 (18.78) 84 914 (65.90)
2012 133 497 14 517 (10.87) 6 160 (4.61) 24 056 (18.02) 88 764 (66.49)
Admission number change












years, mean ± sd
2007 74.15 ± 12.05 70.49 ± 11.43 73.60 ± 11.48 74.31 ± 11.90 74.64 ± 12.13
2008 74.25 ± 12.16 70.60 ± 11.75 73.36 ± 11.87 74.56 ± 11.96 74.72 ± 12.22
2009 74.35 ± 12.20 70.58 ± 11.83 73.58 ± 11.76 74.77 ± 12.09 74.84 ± 12.22
2010 74.45 ± 12.31 70.86 ± 11.79 74.02 ± 11.75 74.89 ± 12.20 74.92 ± 12.37
2011 74.47 ± 12.34 70.50 ± 11.88 73.80 ± 11.91 74.99 ± 12.24 75.01 ± 12.36
2012 74.97 ± 12.17 71.45 ± 11.57 74.26 ± 11.86 75.50 ± 12.07 75.46 ± 12.21
Age change












years, mean ± sd
2007 10.89 ± 10.43 19.16 ± 19.01 13.38 ± 15.46 11.03 ± 8.98 9.53 ± 7.95
2008 10.74 ± 10.39 18.85 ± 20.48 13.05 ± 11.17 10.93 ± 8.76 9.41 ± 7.89
2009 10.76 ± 9.94 18.44 ± 18.02 12.95 ± 10.77 11.09 ± 9.48 9.39 ± 7.50
2010 10.92 ± 10.11 18.26 ± 18.34 13.18 ± 11.24 11.08 ± 8.78 9.55 ± 7.78
2011 10.74 ± 9.59 17.53 ± 16.51 12.69 ± 10.40 11.07 ± 8.93 9.41 ± 7.48
2012 10.60 ± 9.82 17.32 ± 17.43 12.64 ± 10.39 10.92 ± 8.96 9.28 ± 7.53
Length of stay change













2007 66.60 69.50 66.23 65.62 66.56
2008 66.17 68.49 67.41 65.13 66.09
2009 65.25 67.02 64.97 63.70 65.46
2010 64.91 67.87 66.20 62.95 64.91
2011 64.51 67.11 65.74 62.60 64.55
2012 64.11 65.73 64.98 61.96 64.37
Gender ratio change













2007 8 467 (7.32) 2 411 (23.55) 568 (11.02) 2 998 (11.88) 2 490 (3.32)
2008 8 777 (7.37) 2 441 (22.58) 610 (11.57) 3 068 (12.58) 2 658 (3.38)
2009 9 540 (7.52) 2 618 (21.71) 700 (11.84) 3 365 (14.02) 2 857 (3.46)
2010 9 674 (7.72) 2 679 (20.81) 669 (10.81) 3 217 (13.45) 3 109 (3.78)
2011 9 844 (7.64) 2 809 (20.64) 666 (10.86) 3 199 (13.22) 3 170 (3.73)
2012 10 564 (7.91) 2 961 (20.40) 689 (11.19) 3 385 (14.07) 3 529 (3.98)
Mortality rate change











Abbreviation: NA not applicable
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Fig. 2 Trends in COPD admissions by category between 2007 and 2012 in France
Fig. 1 Trends in COPD admissions between 2007 and 2012 in France displayed by category of admission. Detailed numbers are provided in Table 1
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an increasing of total dedicated expanse). Although costs
were adapted, the overall bill increased along with the
increasing incidence, with a greater part dedicated to
ICU. Third, patterns of causes and in-hospital manage-
ment of COPD followed deep mutations. In proportion,
upper airway infection and cardiac failure increased
while only mortality related to pneumonia increased. A
progressive but massive replacement of chest X-rays by
CT scans has been recorded while less spirometries and
bronchoscopies were performed.
The main strengths of the present study rely on the
exhaustiveness of data collection, largely resulting from
enforced legal reporting obligations. Additionally, we
have limited the classification bias by means of a strictly
standardized patient identification algorithm which is
strict and identical for all and has already been validated
[17], with a view to sideline differential diagnoses and
stays for which patients presenting COPD had not been
admitted because of an exacerbation. Lastly, the fact that
this study spans a period of 6 consecutive years makes
its longitudinal quality a crucial strength potentially
generalizable to most westernized countries.
Weaknesses inherently associated with such studies
(lack of clinical data, missing values of pulmonary
function tests, etc.) impose not to over-interpret any
of those findings. Nonetheless, since 2007, a three-
pronged quality control approach is applied to all
dossiers (involving the coding doctor in charge of the
patient, the dedicated doctor of the institution and the
payer), which is the reason why we started our analysis at
this period. We selected stays where COPD was quoted as
the primary diagnosis only to limit the risk of coding bias
especially in non specialized centres; subsequently our
findings are quite specific of the disease but probably
underestimated. Biases related to the epidemiological
nature of the database are incontrovertible why trends
assessed during six consecutive years likely represent the
most meaningful part of the present study. Indeed, the
fact that less spirometries were performed can diminish
the rate of confirmation of COPD diagnoses, thus limiting
the generalizability of the findings. This is highly true in
ICU, but potentially also in non expert centres. Note-
worthy, spirometry is rarely performed during exacerba-
tion with the aim of confirming the diagnosis but rather
to assess severity and/or as a discharge criteria [18].
The increasing incidence of COPD admissions observed
here is different from what was reported in Spain and
more generally in the Westernized countries [7, 19] in
Fig. 3 Trends in associated diagnosis with COPD admissions and related mortalities between 2007 and 2012. Detailed data are provided in
Additional file 1: Table SA4
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studies that used a very similar methodology. The defin-
ition of COPD may vary throughout these countries as a
potential explanation [20]. A different level of severity re-
stricted to France is another option; for instance the his-
tory of coal-mining as shown by our regional findings may
contribute to these differences. The trends show that age
and proportion of women increase with time. Besides,
length of stay appears to shorten progressively.
The persistent increasing in-hospital mortality is surpris-
ing when considering the improvement in COPD overall
management and regarding previous reports [21]. This is
even more worrying since patients were in fact only slightly
older (less than a year) and had no evidence of many coex-
isting diseases. This increase in mortality mainly occurred
among ward-admitted patients – especially when clinical
signs of acute respiratory failures were recorded. Even
though ICU admissions increased, it seems that intermedi-
ate structures dedicated to non-invasive ventilation are still
marginally available (what would correspond to category 3
of our classification), which could in part explain increas-
ing in-ward mortality. It advocates for dedicated care from
pulmonary divisions which should be expanded in the
countries [18]. We need to discuss a decision algorithm to
better adapt the destination ward to the patient needs.
The increases in mortality and incidence of hospitali-
zations are disappointing considering all efforts devel-
oped against COPD burden [1].
All available medications, vaccines, rehabilitation, co-
morbidities screening and management seemed not to
sufficiently change the natural history of the disease.
We reported the five leading causes of exacerbation
recorded as it gathered between 80 to nearly 90 % of
stays, even though the exact definition of exacerbation
and triggers is complex [22]. At most, we should con-
sider our findings at risk of underestimation since this
specificity is inherently related to a lower sensitivity.
Among associated acute diseases, we observed a surpris-
ing increase in mortality related to pneumonia, leading
to discuss several possible explanations. First, coding
bias is unlikely since coding rules remained unchanged
during the study period. Second, a change in the level of
virulence of potential pathogens seems unlikely. Third,
variations in Influenza or Streptococcus pneumonia
vaccines effectiveness cannot be specifically addressed. A
tendency to reduce the rate of vaccination in the general
population and moreover in the elderly have been
recorded in many countries as in France due to media-
transmitted false fears of side effects, sometimes initiated
Fig. 4 Trends in medical acts performed during COPD hospitalizations for exacerbations. (TTE = trans-thoracic echocardiography). Detailed data
are provided in Additional file 1: Table SA5
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by health care providers. Increasing use of ICS in COPD
is again highly debatable regarding these observations.
Antibiotics resistance is another possible explanation but
currently available data are not supporting this hypoth-
esis [23, 24]. Finally, the increasing use of CT-scan could
have led to more diagnoses of pneumonia. Conversely,
increasing incidence of upper airway infection remained
associated with stable mortality rates. Cardiac failure
was increasingly reported as a trigger of severe COPD
exacerbations, which could partly relate to the increasing
Fig. 5 5a Seasonal changes in admissions (short dashed line) and deaths (solid line) due to COPD exacerbations in France from 2007 to 2012. Flu
cases are reported on the same graph (long dashed line). 5b. Trends in COPD admissions and deaths in France among different categories
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availability of NT-pro BNP assessment [19]. Of note,
prevalence of pulmonary embolism in the context of
COPD admission remained extremely stable and rare
despite the increasing use of the CT scan– although
details of CT acquisitions (i.e. suitable for detection of
pulmonary embolism or not) were unavailable.
The geographic distribution of age-standardized
hospitalization rates showed a very heterogeneous distri-
bution, with more hospitalizations in the north of
France, a historical mining region. Interestingly, the
regions where the incidence increased the most are not
the same and it can be hypothesized that occupational
COPD is progressively vanishing. Data obtained from
the monitoring of climatic and air pollution variables
will probably be important to cross with the present
epidemiological data in order to identify potential warn-
ings usable at the individual level.
We found a relationship with socioeconomic data, a
finding largely reported before. More unexpected,
COPD admissions increased over the 6-year period of
the study in the wealthiest areas, suggesting a change
in the profile of COPD toward a richer, more femin-
ine and less occupationally-exposed population.
Seasonality of admissions and deaths were reported
before [25]. In the present data base, the peak of
admission was disconnected from the FLU-peak some
but not all years, and this represents a critical field of
investigation.
This fact questions the immunization efficiency its use
and acceptance within the COPD population with a real
yearly variability.
Direct costs increased significantly (+10.9 %): although
the established care package decreased over time, this
evolution was overtaken by the increasing number of
admissions. The relative contribution of each category to
the overall costs was stable. The increasing number of
ICU-admissions has been compensated by a decrease in
the care package.
In the end, 34 % of the total costs came from the ICU
contribution (which gained 4 % of the total expenditure)
while accounting for 15.50 % of the total admissions.
The underlying motivation of this study was to identify
areas of improvement. Interesting tools have been elabo-
rated for more accurate identification of patients who
should be admitted [26] while ambulatory management
of COPD exacerbation at home was shown to be safe
and efficient in carefully selected patients eligible to
dedicated home management organizations [27].
Conclusion
In conclusion, the trends reported here (notably the
increasing incidence, costs and mortality of severe
COPD exacerbations) represent a major warning for in-
stitutions, physicians and patients and should lead to
extensively rethink COPD management plans and the
allocation of dedicated health care resources in France.
Additional file
Additional file 1: Table SA1. COPD hospitalizations and definitions of
severity categories (sorting rules according to ICD-10) [17]. Table SA2.
Leading cause associated with COPD admissions. Table SA3. Trends in
Fig. 6 Geographical distribution of COPD hospitalizations (age-standardized) in France a incidence of admissions in 2012 (the darker, the greater
the prevalence) and b regional trends in COPD hospitalizations between 2007 and 2012 (the darker, the greater the increase)
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admissions-related costs among different categories of severity.
Table SA4. Cause of COPD admissions. Only five leading causes are
mentioned. Table SA5. Top seven medical acts performed during
hospitalizations for COPD exacerbations. 2007 and 2012 data and
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